LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

January 18, 2024 | Comments Off on LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study

BMC Cancer 2023 December 7 [Link] Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya Abstract Background:…

Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

January 17, 2024 | Comments Off on Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma…

Case Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history

January 16, 2024 | Comments Off on Case Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history

Frontiers in Cardiovascular Medicine 2023 November 20 [Link] Daniel Wang, Yung Hsuan Wang, Sung Chao Chu Abstract Background: Primary pericardial mesothelioma (PPM) is an exceedingly rare malignant cancer and has…

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

January 15, 2024 | Comments Off on Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

JTO Clinical and Research Reports 2023 October 12 [Link] Arkadiusz Z Dudek 1 2, Min X Xi 1, Katherine A Scilla 3, Hirva Mamdani 4, Benjamin C Creelan 5, Andreas…

Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma

January 12, 2024 | Comments Off on Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma

International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only…

Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso

January 11, 2024 | Comments Off on Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso

Journal of Thoracic Oncology 2023 November 15 [Link] N McNamee, C Harvey, L Gray, T Khoo, L Lingam, B Zhang, U Nindra, P Y Yip, A Pal, T Clay, S…

Formalin-Fixed Paraffin-Embedded Proteomics of Malignant Mesothelioma and New Candidate Biomarkers Thioredoxin and Superoxide Dismutase 2 for Immunohistochemistry

January 10, 2024 | Comments Off on Formalin-Fixed Paraffin-Embedded Proteomics of Malignant Mesothelioma and New Candidate Biomarkers Thioredoxin and Superoxide Dismutase 2 for Immunohistochemistry

Laboratory Investigation 2023 November [Link] Takuya Hiratsuka, Akihiko Yoshizawa, Tatsuya Endo, Takushi Yamamoto, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract The pathogenesis of malignant mesothelioma (MM) has been extensively investigated, focusing on…

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

January 9, 2024 | Comments Off on Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

European Journal of Cancer 2024 January [Link] Diego de Miguel-Perez, Edward M Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A Pinto, Alessandro Russo, Giancarlo Troncone,…

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers

January 8, 2024 | Comments Off on Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers

Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM)…

The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy

January 5, 2024 | Comments Off on The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy

Journal of Thoracic Oncology 2023 November 23 [Link] Andre E Nel, Elizabeth N Pavlisko, Victor L Roggli Abstract Despite efforts to ban asbestos mining and manufacturing, mesothelioma deaths in the…

Categories